Company / Shareholders' Equity
Opus Genetics, Inc. Shareholders' Equity History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$6.7M
FY2025
5-year range
-$13.5M / $49.9M
FY2021-FY2025
Trend
-86.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $46M to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2025 with a 3-year CAGR of -32.9%.
Declined from $46M to $7M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -32.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -32.9%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 86.5% year-over-year.
- Peak shareholders' equity was recorded in FY2024.
- Lowest shareholders' equity in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.7M | -86.5% |
| FY2024 | $49.9M | +7.9% |
| FY2023 | $46.2M | +108.1% |
| FY2022 | $22.2M | +265.0% |
| FY2021 | -$13.5M | -241.3% |
| FY2013 | $9.5M | -8.3% |
| FY2011 | $10.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026